FBXL20

Across TCGA pan-cancer cohorts, FBXL20 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of FBXL20’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FBXL20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FBXL20 is over-expressed in tumor, although a few such as COAD and LUSC show the opposite, repressed pattern.

HNSC, KIRP, and LIHC are the cancer types where FBXL20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXL20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.556	<.001	12	view →
KIRP	All	II,III,IV	+0.686	<.001	11	view →
LIHC	Female	All	+0.523	<.001	6	view →
CHOL	Female	All	+1.640	<.001	5	view →
KIRC	All	All	+0.256	<.001	4	view →
PRAD	All	All	+0.234	.009	2	view →
COAD	Female	All	−0.286	.030	1	view →
LUSC	Male	All	−0.280	.008	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

FBXL20–HNSC

Open the HNSC breakdown →